Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells.

The FDA said Amgen’s Prolia may lead to low levels of calcium, or hypocalcemia. The osteoporosis drug’s black box warning follows an FDA review of Centers for Medicare & Medicaid Services ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the RANK ligand inhibitor can be challenging to navigate. "I don't think we ...

Teva shared that the Food and Drug Administration has accepted, and the European Medicines Agency has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s Prolia (denosumab).

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. | Amgen ...

Medicare sets certain guidelines for professionals to bill for the use of Prolia. Learn more here.

Original Medicare, Part D, and Medicare Advantage will generally all provide coverage for the osteoporosis drug Prolia. Learn more here.

The denosumab biosimilars Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) are now commercially available in the US, according to Celltrion.

Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence ® (denosumab-bnht) and Bomyntra ® (denosumab-bnht) - in the United States.